<DOC>
	<DOCNO>NCT00002565</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . It yet know combination chemotherapy regimen effective intermediate-grade immunoblastic non-Hodgkin 's lymphoma . PURPOSE : Randomized phase III trial compare effectiveness two combination chemotherapy regimens treat patient intermediate-grade immunoblastic non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Intermediate-Grade Immunoblastic Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Compare , randomize setting , time treatment failure survival patient poor-prognosis intermediate-grade immunoblastic lymphoma treat standard regimen CHOP ( cyclophosphamide , doxorubicin , vincristine , prednisone ) versus new alternate triple therapy ( ATT ) IdSHAP ( idarubicin , cisplatin , cytarabine , methylprednisolone ) , BIdCOS ( idarubicin , vincristine , bleomycin , cyclophosphamide , methylprednisolone ) , MINE ( mesna , ifosfamide , mitoxantrone , etoposide ) . II . Compare complete response rate achieve ATT versus standard CHOP . III . Assess feasibility deliver full standard dos chemotherapy patient 60 year age receive granulocyte colony stimulate factor support . IV . Compare predictive capability M.D . Anderson Tumor Score System versus International Index System . OUTLINE : Randomized study . The following acronym use : ARA-C Cytarabine , NSC-63878 BLEO Bleomycin , NSC-125066 CDDP Cisplatin , NSC-119875 CTX Cyclophosphamide , NSC-26271 DHAD Mitoxantrone , NSC-301739 DOX Doxorubicin , NSC-123127 G-CSF Granulocyte Colony-Stimulating Factor ( source unspecified ) IDA Idarubicin , NSC-256439 IFF Ifosfamide , NSC-109724 MePRDL Methylprednisolone succinate Mesna Mercaptoethane sulfonate , NSC-113891 PRED Prednisone , NSC-10023 VCR Vincristine , NSC-67574 VP-16 Etoposide , NSC-141540 Arm I : Sequential 4- , 5- , 3-Drug Combination Chemotherapy . IdSHAP : IDA/CDDP/ARA-C/MePRDL ; follow BIdCOS : BLEO/IDA/CTX/VCR/MePRDL ; follow MINE : Mesna/IFF/DHAD/VP-16 . Arm II : 4-Drug Combination Chemotherapy . CHOP : CTX/DOX/VCR/PRED . PROJECTED ACCRUAL : 218 evaluable patient accrue approximately 31 month multicenter study . If either arm significantly inferior interim analyse 31 60 treatment failure , consideration give early closure .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Previously untreated nonHodgkin 's lymphoma ( NHL ) one follow histology : Diffuse large cell Follicular large noncleaved cell Diffuse mix cell Immunoblastic At least 2 follow poorprognosis factor require : Age 60 Performance status great 1 Any elevation LDH More 1 extranodal site Ann Arbor stage III IV T Bcell NHL eligible meeting criterion No primary CNS lymphoma Brain involvement eligible primary PATIENT CHARACTERISTICS : Age : Over 15 Performance status : Any status Hematopoietic : ( unless secondary tumor ) Absolute granulocyte count least 1,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL Elevation secondary tumor discuss study chairman Renal : ( unless secondary tumor ) Creatinine great 1.5 mg/dL Cardiovascular : Left ventricular ejection fraction great 55 % echocardiography Pulmonary : No chronic obstructive restrictive lung disease Pulmonary consultation require case doubt Other : No HIV infection No prior malignancy less 90 % 5year survival probability No patient unable unlikely adhere treatment geographic , economic , emotional , social factor No unwillingness accept blood product transfusion supportive measure ( e.g. , antibiotic ) PRIOR CONCURRENT THERAPY : No prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
</DOC>